VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Nabtesco Corporation vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Nabtesco Corporation
6268 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Nabtesco Corporation's moat claims, evidence, and risks.
View 6268 analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Nabtesco Corporation leads (91 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Nabtesco Corporation has 4 segments (34.2% in Component Solutions Business); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Primary market structure: Quasi-Monopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Nabtesco Corporation has 5 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Nabtesco Corporation
Component Solutions Business
Precision reduction gears (RV reducers) for industrial robot joints
Global
Industrial robot manufacturers (OEMs)
Precision motion-control component supplier
34.2%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Nabtesco Corporation strengths
Gilead Sciences, Inc. strengths
Segment mix
Nabtesco Corporation segments
Full profile >Component Solutions Business
Quasi-Monopoly
Transport Solutions Business
Oligopoly
Accessibility Solutions Business
Quasi-Monopoly
Other Businesses
Quasi-Monopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.